<DOC>
	<DOCNO>NCT01631396</DOCNO>
	<brief_summary>The study prospective , single center , double arm study aim comparison 2 commercial neuromuscular block reversal drug : Neostigmine ( Cooper S.A. ) Sugammadex ( MSD ) . A fast recovery neuromuscular block expect patient receive Sugammadex protocol high importance anesthesia morbid obese patient bariatric surgery .</brief_summary>
	<brief_title>Comparison Two Neuromuscular Anesthetics Reversal Obese Patient Undergoing Bariatric Surgery</brief_title>
	<detailed_description />
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>1 . Morbidly obese male female patient age 2065 candidate bariatric surgery . 2 . Patients read understand fundamental nature clinical protocol . 3 . Patients must sign Informed Consent Form . 1 . Patients treat drug might interact Rocuronium . 2 . Patients history malignant hyperthermia . 3 . Patients significant renal disease . 4 . Patients know allergy one drug use anesthesia . 5 . Patients know muscular disease . 6 . Patients severe cardiovascular disease ( NYHA &gt; 2 ) 7 . Breast feed patient 8 . Patients refuse follow clinical protocol . 9 . Patients participate different clinical trial . 10 . Patients refuse sign Informed Consent Form 11 . Physician 's objection .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Morbid obesity</keyword>
	<keyword>Bariatric Surgery</keyword>
	<keyword>Neuromuscular block reversal</keyword>
</DOC>